Danaher (NYSE:DHR - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Tuesday, July 22nd. Analysts expect the company to announce earnings of $1.64 per share and revenue of $5.83 billion for the quarter. Danaher has set its FY 2025 guidance at 7.600-7.750 EPS.
Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. On average, analysts expect Danaher to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.
Danaher Price Performance
Shares of Danaher stock traded down $5.01 during midday trading on Tuesday, reaching $192.74. The company had a trading volume of 4,521,829 shares, compared to its average volume of 3,517,816. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $137.94 billion, a price-to-earnings ratio of 37.43, a price-to-earnings-growth ratio of 2.88 and a beta of 0.77. The stock has a fifty day simple moving average of $196.06 and a 200 day simple moving average of $205.89. Danaher has a 1-year low of $171.00 and a 1-year high of $281.70.
Danaher Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.66%. Danaher's payout ratio is 24.85%.
Wall Street Analyst Weigh In
A number of brokerages have commented on DHR. UBS Group decreased their price objective on Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Barclays reissued an "overweight" rating and issued a $225.00 price target (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Robert W. Baird reduced their target price on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating for the company in a research note on Wednesday, April 23rd. Wolfe Research cut their price target on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a research report on Monday, April 7th. Finally, Wells Fargo & Company cut their price target on shares of Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $248.43.
View Our Latest Research Report on DHR
Insider Buying and Selling
In related news, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president directly owned 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by insiders.
Danaher Company Profile
(
Get Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
